Discover how QLS1209, a novel PKMYT1 inhibitor, is revolutionizing cancer treatment through synthetic lethality targeting CCNE1-amplified and FBXW7-mutated tumors.
Exploring how hyperactivating cancer pathways can be a novel synthetic lethality approach in oncology